US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-22 10:54:16 Source:entertainmentViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:US Open champ Coco Gauff urges young Americans to vote
Next:Vatican makes fresh overture to China, reaffirms that Catholic Church is no threat to sovereignty
You may also like
- New Zealand Black Caps fans look to Twenty20 World Cup with hope, trepidation
- REVEALED: The eye
- Moment car almost smashes into a horse as police release footage of heart
- Pictured: The most Instagrammable Michelin
- Haiti’s international airport reopens after gang violence
- REVEALED: The VERY strict 'decorum rules' that passengers aboard NUDE cruise have to follow
- I'm a cruise ship worker
- 'We always hug before take
- Police raid the headquarters of the Milan